10-K Filing

Astrana Health, Inc. CIK: 1083446 FY 2016

Filing Information

Form Type	10-K
Accession Number	`0001144204-17-034759`
Period End Date	20170331
Filing Date	20170629
Fiscal Year	2016
Fiscal Period	FY
XBRL Instance	ameh-20170331.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 76 Income Statement 38 Cash Flow Statement 119 Stockholders Equity 28

Balance Sheet 76 line items

Line Item	Tag	Value	Unit	Period
Accounts receivable, net of allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$475.08K	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$601.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$9.27M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$5.01M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$8.66M	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $475,080 and $601,000 at March 31, 2017 and 2016, respectively	`AccountsReceivableNetCurrent`	$3.39M	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $475,080 and $601,000 at March 31, 2017 and 2016, respectively	`AccountsReceivableNetCurrent`	$5.51M	USD	Point-in-time
Other receivables	`AccountsAndOtherReceivablesNetCurrent`	$581.21K	USD	Point-in-time
Other receivables	`AccountsAndOtherReceivablesNetCurrent`	$464.08K	USD	Point-in-time
Due from Affiliates	`DueFromAffiliateCurrent`	$18.31K	USD	Point-in-time
Due from Affiliates	`DueFromAffiliateCurrent`	$20.50K	USD	Point-in-time
Common Stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$293.83K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$269.17K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$13.56M	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$14.92M	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	5.88M	shares	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	6.03M	shares	Point-in-time
Deferred financing costs, net	`DeferredFinanceCostsNoncurrentNet`	-	USD	Point-in-time
Deferred financing costs, net	`DeferredFinanceCostsNoncurrentNet`	$37.93K	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	6.03M	shares	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	5.88M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.21M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.25M	USD	Point-in-time
Restricted cash	`RestrictedCashAndInvestmentsCurrent`	$530.00K	USD	Point-in-time
Restricted cash	`RestrictedCashAndInvestmentsCurrent`	$765.06K	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$2.35M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$1.90M	USD	Point-in-time
Goodwill	`Goodwill`	$2.17M	USD	Point-in-time
Goodwill	`Goodwill`	$1.62M	USD	Point-in-time
Goodwill	`Goodwill`	$1.62M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$216.44K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$225.36K	USD	Point-in-time
TOTAL ASSETS	`Assets`	$19.57M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$20.64M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$4.57M	USD	Point-in-time
Accounts payable and accrued liabilities	`AccountsPayableAndAccruedLiabilitiesCurrent`	$7.88M	USD	Point-in-time
Medical liabilities	`MedicalLiabilitiesCurrent`	$2.67M	USD	Point-in-time
Medical liabilities	`MedicalLiabilitiesCurrent`	$1.77M	USD	Point-in-time
Convertible note payable, net of debt issuance cost of $161,000	`ConvertibleNotesPayableCurrent`	-	USD	Point-in-time
Convertible note payable, net of debt issuance cost of $161,000	`ConvertibleNotesPayableCurrent`	$4.83M	USD	Point-in-time
Lines of credit	`LinesOfCreditCurrent`	$62.50K	USD	Point-in-time
Lines of credit	`LinesOfCreditCurrent`	$188.76K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$7.43M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$14.54M	USD	Point-in-time
Note payable - related party	`NotesPayableRelatedPartiesNoncurrent`	$5.00M	USD	Point-in-time
Note payable - related party	`NotesPayableRelatedPartiesNoncurrent`	-	USD	Point-in-time
Warrant liability	`DerivativeLiabilitiesNoncurrent`	-	USD	Point-in-time
Warrant liability	`DerivativeLiabilitiesNoncurrent`	$2.81M	USD	Point-in-time
Deferred rent liability	`DeferredRentCreditNoncurrent`	$728.88K	USD	Point-in-time
Deferred rent liability	`DeferredRentCreditNoncurrent`	$747.42K	USD	Point-in-time
Deferred tax liability	`DeferredTaxLiabilities`	$43.48K	USD	Point-in-time
Deferred tax liability	`DeferredTaxLiabilities`	$83.67K	USD	Point-in-time
Total liabilities	`Liabilities`	$11.02M	USD	Point-in-time
Total liabilities	`Liabilities`	$20.37M	USD	Point-in-time
COMMITMENTS AND CONTINGENCIES (Note 10)	`CommitmentsAndContingencies`	-	USD	Point-in-time
COMMITMENTS AND CONTINGENCIES (Note 10)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Series A Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series B Preferred stock); 1,111,111 issued and outstanding as of March 31, 2016, Liquidation preference of $9,999,999 at March 31, 2016	`TemporaryEquityCarryingAmountAttributableToParent`	$7.08M	USD	Point-in-time
Common stock, par value $0.001; 100,000,000 shares authorized, 6,033,518 and 5,876,852 shares issued and outstanding at March 31, 2017 and 2016, respectively	`CommonStockValue`	$6.03K	USD	Point-in-time
Common stock, par value $0.001; 100,000,000 shares authorized, 6,033,518 and 5,876,852 shares issued and outstanding at March 31, 2017 and 2016, respectively	`CommonStockValue`	$5.88K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$26.33M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$23.52M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-28.68M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-37.65M	USD	Point-in-time
Stockholders deficit attributable to Apollo Medical Holdings, Inc.	`StockholdersEquity`	$-1.27M	USD	Point-in-time
Stockholders deficit attributable to Apollo Medical Holdings, Inc.	`StockholdersEquity`	$-353.88K	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$2.74M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$624.25K	USD	Point-in-time
Total stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-990.18K	USD	Point-in-time
Total stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.47M	USD	Point-in-time
Total stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$270.37K	USD	Point-in-time
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$20.64M	USD	Point-in-time
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$19.57M	USD	Point-in-time

Income Statement 38 line items

Line Item	Tag	Value	Unit	Period
Net revenues	`Revenues`	$44.05M	USD	Annual
Net revenues	`Revenues`	$57.43M	USD	Annual
Cost of services	`CostOfServices`	$34.00M	USD	Annual
Cost of services	`CostOfServices`	$48.74M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$16.96M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$18.58M	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$351.40K	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$645.74K	USD	Annual
Total costs and expenses	`OperatingExpenses`	$51.31M	USD	Annual
Total costs and expenses	`OperatingExpenses`	$67.96M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-7.27M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-10.54M	USD	Annual
Interest expense	`InterestExpense`	$542.30K	USD	Annual
Interest expense	`InterestExpense`	$82.91K	USD	Annual
Gain (loss) on change in fair value of warrant and conversion feature liabilities	`GainLossOnDerivativeInstrumentsNetPretax`	$-408.69K	USD	Annual
Gain (loss) on change in fair value of warrant and conversion feature liabilities	`GainLossOnDerivativeInstrumentsNetPretax`	$1.63M	USD	Annual
Gain on deconsolidation of variable interest entity	`DeconsolidationGainOrLossAmount`	-	USD	Annual
Gain on deconsolidation of variable interest entity	`DeconsolidationGainOrLossAmount`	$242.41K	USD	Annual
Loss on debt extinguishment	`ExtinguishmentOfDebtGainLossNetOfTax`	$-266.37K	USD	Annual
Loss on debt extinguishment	`ExtinguishmentOfDebtGainLossNetOfTax`	-	USD	Annual
Other income	`OtherNonoperatingIncomeExpense`	$14.70K	USD	Annual
Other income	`OtherNonoperatingIncomeExpense`	$239.06K	USD	Annual
Total other income (expense), net	`NonoperatingIncomeExpense`	$-978.30K	USD	Annual
Total other income (expense), net	`NonoperatingIncomeExpense`	$1.81M	USD	Annual
Loss before benefit from income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-8.24M	USD	Annual
Loss before benefit from income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-8.73M	USD	Annual
Benefit from income taxes	`IncomeTaxExpenseBenefit`	$-47.49K	USD	Annual
Benefit from income taxes	`IncomeTaxExpenseBenefit`	$-71.04K	USD	Annual
Net loss	`ProfitLoss`	$-8.17M	USD	Annual
Net loss	`ProfitLoss`	$-8.68M	USD	Annual
Net income attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$1.17M	USD	Annual
Net income attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$287.90K	USD	Annual
Net loss attributable to Apollo Medical Holdings, Inc.	`NetIncomeLoss`	$-8.97M	USD	Annual
Net loss attributable to Apollo Medical Holdings, Inc.	`NetIncomeLoss`	$-9.34M	USD	Annual
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-1.79	USD	Annual
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-1.49	USD	Annual
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	5.21M	shares	Annual
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	6.00M	shares	Annual

Cash Flow Statement 119 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-8.17M	USD	Annual
Net loss	`ProfitLoss`	$-8.68M	USD	Annual
Provision for doubtful accounts	`ProvisionForDoubtfulAccounts`	$385.60K	USD	Annual
Provision for doubtful accounts	`ProvisionForDoubtfulAccounts`	$435.84K	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$351.40K	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$645.74K	USD	Annual
Loss on disposal of assets	`GainLossOnSaleOfPropertyPlantEquipment`	$-6.94K	USD	Annual
Loss on disposal of assets	`GainLossOnSaleOfPropertyPlantEquipment`	$-476.75K	USD	Annual
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$40.19K	USD	Annual
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-127.74K	USD	Annual
Stock-based compensation expense	`AllocatedShareBasedCompensationExpense`	$1.11M	USD	Annual
Stock-based compensation expense	`AllocatedShareBasedCompensationExpense`	$1.10M	USD	Annual
Gain on deconsolidation of variable interest entity	`DeconsolidationGainOrLossAmount`	-	USD	Annual
Gain on deconsolidation of variable interest entity	`DeconsolidationGainOrLossAmount`	$242.41K	USD	Annual
Loss on debt extinguishment	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Loss on debt extinguishment	`GainsLossesOnExtinguishmentOfDebt`	$-266.37K	USD	Annual
Amortization of deferred financing costs	`AdjustmentForAmortization`	$44.81K	USD	Annual
Amortization of deferred financing costs	`AdjustmentForAmortization`	$94.91K	USD	Annual
Write-off of capitalized offering costs	`WriteoffOfCapitalizedOfferingCosts`	-	USD	Annual
Write-off of capitalized offering costs	`WriteoffOfCapitalizedOfferingCosts`	$513.65K	USD	Annual
Amortization adjustment to debt discount	`AmortizationOfDebtDiscountPremium`	$-29.98K	USD	Annual
Amortization adjustment to debt discount	`AmortizationOfDebtDiscountPremium`	-	USD	Annual
Change in fair value of warrant and conversion feature liability	`GainLossOnDerivativeInstrumentsNetPretax`	$-408.69K	USD	Annual
Change in fair value of warrant and conversion feature liability	`GainLossOnDerivativeInstrumentsNetPretax`	$1.63M	USD	Annual
Impairment of goodwill and intangible assets	`GoodwillAndIntangibleAssetImpairment`	$207.28K	USD	Annual
Impairment of goodwill and intangible assets	`GoodwillAndIntangibleAssetImpairment`	$68.31K	USD	Annual
Impairment of goodwill and intangible assets	`GoodwillAndIntangibleAssetImpairment`	$207.28K	USD	Point-in-time
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$27.20K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$2.78M	USD	Annual
Other receivables	`IncreaseDecreaseInOtherReceivables`	$-283.70K	USD	Annual
Other receivables	`IncreaseDecreaseInOtherReceivables`	$-113.30K	USD	Annual
Due from affiliates	`IncreaseDecreaseDueFromAffiliates`	$-15.89K	USD	Annual
Due from affiliates	`IncreaseDecreaseDueFromAffiliates`	$-2.19K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets`	$92.18K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets`	$10.16K	USD	Annual
Deferred financing costs	`IncreaseDecreaseInDeferredCharges`	$43.33K	USD	Annual
Deferred financing costs	`IncreaseDecreaseInDeferredCharges`	-	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-3.18K	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$8.92K	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$3.65M	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$1.02M	USD	Annual
Deferred rent liability	`IncreaseDecreaseInOtherDeferredLiability`	$53.51K	USD	Annual
Deferred rent liability	`IncreaseDecreaseInOtherDeferredLiability`	$57.91K	USD	Annual
Medical liabilities	`IncreaseDecreaseInMedicalLiabilities`	$1.41M	USD	Annual
Medical liabilities	`IncreaseDecreaseInMedicalLiabilities`	$-902.48K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-1.84M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-8.14M	USD	Annual
Change in restricted cash	`IncreaseDecreaseInRestrictedCash`	-	USD	Annual
Change in restricted cash	`IncreaseDecreaseInRestrictedCash`	$235.06K	USD	Annual
Proceeds from sale of ACC assets	`ProceedsFromDivestitureOfBusinesses`	$15.00K	USD	Annual
Proceeds from sale of ACC assets	`ProceedsFromDivestitureOfBusinesses`	-	USD	Annual
Decrease in cash and cash equivalents resulting from deconsolidation of variable interest entities	`CashAndCashEquivalentsDecreaseFromDeconsolidationOfVariableInterestEntity`	-	USD	Annual
Decrease in cash and cash equivalents resulting from deconsolidation of variable interest entities	`CashAndCashEquivalentsDecreaseFromDeconsolidationOfVariableInterestEntity`	$858.67K	USD	Annual
Property and equipment acquired	`PaymentsToAcquirePropertyPlantAndEquipment`	$297.56K	USD	Annual
Property and equipment acquired	`PaymentsToAcquirePropertyPlantAndEquipment`	$262.11K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-1.39M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-247.11K	USD	Annual
Proceeds from issuance of convertible note payable	`ProceedsFromConvertibleDebt`	-	USD	Annual
Proceeds from issuance of convertible note payable	`ProceedsFromConvertibleDebt`	$4.99M	USD	Annual
Proceeds from issuance of note payable - related party	`ProceedsFromRelatedPartyDebt`	$5.00M	USD	Annual
Proceeds from issuance of note payable - related party	`ProceedsFromRelatedPartyDebt`	-	USD	Annual
Repayments on convertible notes	`RepaymentsOfOtherShortTermDebt`	$470.00K	USD	Annual
Repayments on convertible notes	`RepaymentsOfOtherShortTermDebt`	-	USD	Annual
Proceeds from notes payable	`ProceedsFromNotesPayable`	$100.00K	USD	Annual
Proceeds from notes payable	`ProceedsFromNotesPayable`	$400.00K	USD	Annual
Principal payments on notes payable	`PrincipalPaymentsOnTermNotePayable`	$400.00K	USD	Annual
Principal payments on notes payable	`PrincipalPaymentsOnTermNotePayable`	$6.53M	USD	Annual
Proceeds from line of credit	`ProceedsFromLinesOfCredit`	-	USD	Annual
Proceeds from line of credit	`ProceedsFromLinesOfCredit`	$235.00K	USD	3 Qtrs
Proceeds from line of credit	`ProceedsFromLinesOfCredit`	$112.50K	USD	Annual
Repayments on lines of credit	`RepaymentsOfLinesOfCredit`	$150.00K	USD	Annual
Repayments on lines of credit	`RepaymentsOfLinesOfCredit`	$1.01M	USD	Annual
Distributions to noncontrolling interest	`PaymentsToMinorityShareholders`	$702.64K	USD	Annual
Distributions to noncontrolling interest	`PaymentsToMinorityShareholders`	$1.20M	USD	Annual
Proceeds from exercise of warrants and vested restricted stock	`ProceedsFromIssuanceOfWarrantsAndVestedRestrictedStock`	-	USD	Annual
Proceeds from exercise of warrants and vested restricted stock	`ProceedsFromIssuanceOfWarrantsAndVestedRestrictedStock`	$172.07K	USD	Annual
Proceeds from issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Proceeds from issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$200.00K	USD	Annual
Payment to noncontrolling interest for equity interest	`PaymentToNoncontrollingInterestForEquityInterestAmount`	$-251.85K	USD	Annual
Payment to noncontrolling interest for equity interest	`PaymentToNoncontrollingInterestForEquityInterestAmount`	-	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$8.92M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$6.34M	USD	Annual
Net change in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$4.26M	USD	Annual
Net change in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-605.80K	USD	Annual
Cash and cash equivalents, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$9.27M	USD	Point-in-time
Cash and cash equivalents, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$5.01M	USD	Point-in-time
Cash and cash equivalents, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$8.66M	USD	Point-in-time
Cash and cash equivalents, end of year	`CashAndCashEquivalentsAtCarryingValue`	$9.27M	USD	Point-in-time
Cash and cash equivalents, end of year	`CashAndCashEquivalentsAtCarryingValue`	$5.01M	USD	Point-in-time
Cash and cash equivalents, end of year	`CashAndCashEquivalentsAtCarryingValue`	$8.66M	USD	Point-in-time
Interest paid	`InterestPaid`	$23.53K	USD	Annual
Interest paid	`InterestPaid`	$521.34K	USD	Annual
Income taxes paid	`IncomeTaxesPaid`	$176.59K	USD	Annual
Income taxes paid	`IncomeTaxesPaid`	$30.90K	USD	Annual
Issuance of common stock on conversion of 8% warrants and notes	`NoncashOrPartnoncashIssuanceOfCommonStockForExtinguishmentOfDebt`	-	USD	Annual
Issuance of common stock on conversion of 8% warrants and notes	`NoncashOrPartnoncashIssuanceOfCommonStockForExtinguishmentOfDebt`	$3.06M	USD	Annual
Issuance of common stock in connection with conversion of 9% notes payable and accrued interest	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$553.85K	USD	Annual
Issuance of common stock in connection with conversion of 9% notes payable and accrued interest	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	-	USD	Annual
Change in noncontrolling interest ownership	`IncreaseDecreaseInNoncontrollingInterestOwnership`	$338.03K	USD	Annual
Change in noncontrolling interest ownership	`IncreaseDecreaseInNoncontrollingInterestOwnership`	-	USD	Annual
Tenant improvement allowance	`TenantImprovementAllowance`	$659.36K	USD	Annual
Tenant improvement allowance	`TenantImprovementAllowance`	-	USD	Annual
Note receivable related to sale of ACC asset	`NotesReceivableRelatedToSaleOfAssets`	$51.00K	USD	Annual
Note receivable related to sale of ACC asset	`NotesReceivableRelatedToSaleOfAssets`	-	USD	Annual
Convertible debt reclassified to accounts payable	`LiabilitiesAssumed1`	-	USD	Annual
Convertible debt reclassified to accounts payable	`LiabilitiesAssumed1`	$100.00K	USD	Annual
Common stock issued for acquisition of intangible assets	`StockIssued1`	$1.31M	USD	Annual
Common stock issued for acquisition of intangible assets	`StockIssued1`	-	USD	Annual
Reclassification of derivative liability to equity	`ReclassificationOfDerivativeLiabilityToEquity`	-	USD	Annual
Reclassification of derivative liability to equity	`ReclassificationOfDerivativeLiabilityToEquity`	$1.18M	USD	Annual
Reclassification of derivative liability to equity	`ReclassificationOfDerivativeLiabilityToEquity`	$1.18M	USD	Point-in-time
Relative fair value of warrant included in debt discount	`FairValueOfWarrantIncludedInDebtDiscount`	-	USD	Annual
Relative fair value of warrant included in debt discount	`FairValueOfWarrantIncludedInDebtDiscount`	$6.88K	USD	Annual
Reclassification of mezzanine equity to permanent equity	`ReclassificationOfMezzanineEquityToPermanentEquity`	-	USD	Annual
Reclassification of mezzanine equity to permanent equity	`ReclassificationOfMezzanineEquityToPermanentEquity`	$7.08M	USD	Annual
Reclassification of noncontrolling interest to due to acquisition of BAHA noncontrolling interest	`ReleaseOfNoncontrollingInterestDueToAcquisitionOfBaha`	$183.41K	USD	Annual
Reclassification of noncontrolling interest to due to acquisition of BAHA noncontrolling interest	`ReleaseOfNoncontrollingInterestDueToAcquisitionOfBaha`	-	USD	Annual
Warrants issuable for debt guarantee	`WarrantsIssuableForDebtGuarantee`	-	USD	Annual
Warrants issuable for debt guarantee	`WarrantsIssuableForDebtGuarantee`	$161.00K	USD	Annual

Stockholders Equity 28 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-990.18K	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.47M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$270.37K	USD	Point-in-time
Net income (loss)	`ProfitLoss`	$-8.17M	USD	Annual
Net income (loss)	`ProfitLoss`	$-8.68M	USD	Annual
Stock-based compensation expense	`StockIssuedDuringPeriodValueShareBasedCompensation`	$1.10M	USD	Annual
Stock-based compensation expense	`StockIssuedDuringPeriodValueShareBasedCompensation`	$1.11M	USD	Annual
Issuance of common stock for exercise of warrants	`StockIssuedDuringPeriodValueExerciseOfWarrants`	$172.00K	USD	Annual
Issuance of common stock for exercise of warrants (in shares)	`StockIssuedDuringPeriodSharesExerciseOfWarrants`	150,000.00	shares	Annual
Issuance of common stock for vested restricted stock	`StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures`	$68.00	USD	Annual
Relative fair value of warrants issued with debt	`AdjustmentsToAdditionalPaidInCapitalWarrantIssued`	$6.88K	USD	Annual
Reclassification of Noncontrolling interest due to acquisition of VIE	`AdjustmentToAdditionalPaidInCapitalReclassificationOfNoncontrollingInterestDueToAcquisitionOfVie`	-	USD	Annual
Issuance of common stock in acquisition	`StockIssuedDuringPeriodValueAcquisitions`	$1.51M	USD	Annual
Distributions to noncontrolling interest	`MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders`	$1.20M	USD	Annual
Distributions to noncontrolling interest	`MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders`	$702.64K	USD	Annual
Reclassification of noncontrolling interest to notes receivable	`ReclassificationOfNoncontrollingInterestToNotesReceivable`	$414.72K	USD	Annual
Net adjustment from change in APS ownership interest	`AdjustmentsToAdditionalPaidInCapitalOther`	$-305.31K	USD	Annual
Conversion of 9% notes to common stock	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$553.85K	USD	Annual
Conversion of 9% notes to common stock	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	-	USD	Annual
Conversion of 8% notes and warrants to common stock	`StockIssuedDuringPeriodValueConversionOfNotesAndWarrants`	$3.06M	USD	Annual
Deconsolidation of VIEs	`NoncontrollingInterestDecreaseFromDeconsolidation`	$1.02M	USD	Annual
Warrants issuable for debt guarantee	`AdjustmentToAdditionalPaidInCapitalWarrantsIssuableForDebtGuarantee`	$161.00K	USD	Annual
Reclassification of mezzanine equity to permanent equity	`StockIssuedDuringPeriodValueConversionOfMezzaineEquityToPermanentEquity`	$7.08M	USD	Annual
Reclassification of derivative liability to equity	`AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature`	$-1.18M	USD	Annual
Issuance of preferred stock and equity warrant	`StockIssuedDuringPeriodValueNewIssues`	$5.00M	USD	Annual
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$-990.18K	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.47M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$270.37K	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.